pain Archives -

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an

Grünenthal takes non-opioid pain drug resiniferatoxin into phase 3

https://pharmaphorum.com/news/grunenthal-takes-non-opioid-pain-drug-resiniferatoxin-into-phase-3/

News/ News/ R&D

Vertex Pharma makes progress in quest for non-opioid pain drug

Phil Taylor Analgesic, NaV1.8, opioid, pain, Vertex Pharma 0 Comment

The search for an alternative to opioid drugs for pain relief has dragged one for decades, with little

Vertex Pharma makes progress in quest for non-opioid pain drug

https://pharmaphorum.com/news/vertex-pharma-makes-progress-in-quest-for-non-opioid-pain-drug/

Close-up image of a firm handshake between two colleagues

News/ News/ Sales and Marketing

Supernus bulks up its Parkinson’s portfolio with Adamas takeover

Phil Taylor Adamas Pharmaceuticals, Flexion Therapeutics, M&A, Pacira, pain, Parkinson's disease, Supernus Pharma 0 Comment

Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas

Supernus bulks up its Parkinson’s portfolio with Adamas takeover

https://pharmaphorum.com/news/supernus-bulks-up-its-parkinsons-portfolio-with-adamas-takeover/

Digital/ News/ News

Scientific study finds music can ‘tune out pain’

Phil Taylor music medicine, pain, Reckitt Benckiser 0 Comment

A study has found that listening to a specially composed music track can achieve “clinically significant” reductions in

Scientific study finds music can ‘tune out pain’

https://pharmaphorum.com/news/scientific-study-finds-music-can-tune-out-pain/

Market Access/ News/ News

EU panel rejects Pfizer’s tanezumab for osteoarthritis pain

Phil Taylor CHMP, Eli Lilly, fasinumab, osteoarthritis, pain, Pfizer, Regeneron, tanezumab, Teva 0 Comment

Any lingering hope that Pfizer may finally get a regulatory approval for its nerve growth factor (NGF) inhibitor

EU panel rejects Pfizer’s tanezumab for osteoarthritis pain

https://pharmaphorum.com/news/eu-panel-rejects-pfizers-tanezumab-for-osteoarthritis-pain/

News/ News/ R&D

Lilly taps Lycia for protein degrader tech in $1.6bn deal

Phil Taylor Eli Lilly, immunology, licensing, Lycia Therapeutics, pain, partnering, protein degradation 0 Comment

Eli Lilly has bolstered its position the fast-emerging area of protein degrader drugs, agreeing a $1.6 billion-plus deal

Lilly taps Lycia for protein degrader tech in $1.6bn deal

https://pharmaphorum.com/news/lilly-taps-lycia-for-protein-degrader-tech-in-1-6bn-deal/

Digital/ News/ News

Older people ‘more likely to engage with digital physiotherapy care’

Phil Taylor digital, digital health, Hinge Health, musculoskeletal, pain, physiotherapy, telehealth 0 Comment

Researchers in the US have found that older people are far more likely to engage with digital physiotherapy

Older people ‘more likely to engage with digital physiotherapy care’

https://pharmaphorum.com/news/older-people-more-likely-to-engage-with-digital-physiotherapy-care/

News/ News/ R&D

Thumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumab

Richard Staines Lilly, osteoarthritis, pain, Pfizer, tanezumab 0 Comment

After more than a decade of fraught clinical development it looks like the end of the line for

Thumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumab

https://pharmaphorum.com/news/fda-experts-give-thumbs-down-for-pfizer-lillys-painkiller-tanezumab/

News/ News/ R&D

FDA worried about Pfizer/Lilly pain drug safety ahead of key meeting

Richard Staines Eli Lilly, osteoarthritis, pain, Pfizer, regulation 0 Comment

After a long and troubled development the fate of Pfizer/Lilly’s tanezumab painkiller injection is in the balance ahead

FDA worried about Pfizer/Lilly pain drug safety ahead of key meeting

https://pharmaphorum.com/news/fda-worried-pfizer-lilly-pain-drug-safety-ahead-of-key-meeting/

Trending

pain

Login